Co-administration of liposomal fasudil and tissue plasminogen activator ameliorated ischemic brain damage in occlusion model rats prepared by photochemically induced thrombosis

2018 ◽  
Vol 495 (1) ◽  
pp. 873-877 ◽  
Author(s):  
Tatsuya Fukuta ◽  
Yosuke Yanagida ◽  
Tomohiro Asai ◽  
Naoto Oku
Keyword(s):  
Plasminogen Activator ◽  
Brain Damage ◽  
Tissue Plasminogen Activator ◽  
Ischemic Brain Damage ◽  
Ischemic Brain ◽  
Occlusion Model ◽  
Tissue Plasminogen

scholarly journals A Combined Treatment with Tacrolimus (FK506) and Recombinant Tissue Plasminogen Activator for Thrombotic Focal Cerebral Ischemia in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window

2002 ◽  
Vol 22 (10) ◽  
pp. 1205-1211 ◽  
Author(s):  
Masashi Maeda ◽  
Yasuhisa Furuichi ◽  
Noriko Ueyama ◽  
Akira Moriguchi ◽  
Natsuki Satoh ◽  
...  
Keyword(s):  
Brain Damage ◽  
Time Window ◽  
Brain Infarction ◽  
Combined Treatment ◽  
Recombinant Tissue Plasminogen Activator ◽  
Ischemic Brain Damage ◽  
Ischemic Brain ◽  
Mca Occlusion ◽  
Tissue Plasminogen ◽  
Therapeutic Time Window

The authors evaluated the therapeutic efficacy of tacrolimus (FK506), administered alone or in combination with recombinant tissue plasminogen activator (t-PA), on brain infarction following thrombotic middle cerebral artery (MCA) occlusion. Thrombotic occlusion of the MCA was induced by a photochemical reaction between rose bengal and green light in Sprague-Dawley rats, and the volume of ischemic brain damage was determined 24 hours later. Intravenous administration of tacrolimus or t-PA dose-dependently reduced the volume of ischemic brain infarction, whether administered immediately or 1 hour after MCA occlusion. When tacrolimus or t-PA was administered 2 hours after MCA occlusion, each drug showed a tendency to reduce ischemic brain damage. However, combined treatment with both drugs resulted in a significant reduction in ischemic brain damage. On administration 3 hours after MCA occlusion, tacrolimus alone showed no effect, and t-PA tended to worsen ischemic brain damage. However, the combined treatment with both drugs not only ameliorated the worsening trend seen with t-PA alone, but also tended to reduce ischemic brain damage. In conclusion, tacrolimus, used in combination with t-PA, augmented therapeutic efficacy on brain damage associated with focal ischemia and extended the therapeutic time window compared to single-drug treatments.

Sign in / Sign up

Export Citation Format

Share Document